Back to School: How biopharma can reboot drug development. Access exclusive analysis here

2MD: Phase IIb data

A double-blind, U.S. Phase IIb trial in 62 CKD patients receiving hemodialysis showed that thrice-weekly 220-770 ng

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE